These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 18379337)

  • 41. Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?
    Vale S
    Exp Biol Med (Maywood); 2008 Aug; 233(8):941-51. PubMed ID: 18535172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuropsychology and ECT: past and future research trends.
    Calev A
    Psychopharmacol Bull; 1994; 30(3):461-9. PubMed ID: 7878183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bifrontal versus bitemporal electroconvulsive therapy in severe manic patients.
    Barekatain M; Jahangard L; Haghighi M; Ranjkesh F
    J ECT; 2008 Sep; 24(3):199-202. PubMed ID: 18772704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can ECT-induced cognitive effects be altered pharmacologically?
    Khan A; Mirolo MH; Mirolo HA; Miller S
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Nov; 17(6):861-73. PubMed ID: 8278598
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of propofol and thiopentone use in electroconvulsive therapy: cognitive and efficacy effects.
    Ingram A; Schweitzer I; Ng CH; Saling MM; Savage G
    J ECT; 2007 Sep; 23(3):158-62. PubMed ID: 17804989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Falls associated with electroconvulsive therapy among the geriatric population: a case report.
    Rao SS; Daly JW; Sewell DD
    J ECT; 2008 Jun; 24(2):173-5. PubMed ID: 18580567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucocorticoid antagonists in neuropsychiatric [corrected] disorders.
    Schatzberg AF; Lindley S
    Eur J Pharmacol; 2008 Apr; 583(2-3):358-64. PubMed ID: 18339372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perspectives of patients and relatives about electroconvulsive therapy: a qualitative study from Vellore, India.
    Rajkumar AP; Saravanan B; Jacob KS
    J ECT; 2006 Dec; 22(4):253-8. PubMed ID: 17143156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical efficacy of unilateral ECT.
    Abrams R; DeVito RA
    Dis Nerv Syst; 1969 Apr; 30(4):262-3. PubMed ID: 4890011
    [No Abstract]   [Full Text] [Related]  

  • 50. [Pharmacologic treatment for cognitive disorders: an update].
    Lestage P
    Therapie; 2000; 55(4):507-12. PubMed ID: 11098728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical trials in children with Down syndrome: issues from a cognitive research perspective.
    Heller JH; Spiridigliozzi GA; Crissman BG; Sullivan-Saarela JA; Li JS; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2006 Aug; 142C(3):187-95. PubMed ID: 16838317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The practice of electroconvulsive therapy in Malawi.
    Selis MA; Kauye F; Leentjens AF
    J ECT; 2008 Jun; 24(2):137-40. PubMed ID: 18580558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying and treating cognitive impairment in bipolar disorder.
    Goldberg JF; Chengappa KN
    Bipolar Disord; 2009 Jun; 11 Suppl 2():123-37. PubMed ID: 19538691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ECT and Pronounced Impairment in Spatial Cognition: The Fallacy of Drawing Conclusions From a Single Case.
    Andrade C; Prasad Y; Devaraj A; Pinto EF; Shukla L
    J ECT; 2018 Jun; 34(2):75-77. PubMed ID: 29324524
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders.
    McIntyre RS; Powell AM; Kaidanovich-Beilin O; Soczynska JK; Alsuwaidan M; Woldeyohannes HO; Kim AS; Gallaugher LA
    Behav Brain Res; 2013 Jan; 237():164-71. PubMed ID: 23000536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contraindicated medication use among patients in a memory disorders clinic.
    Barton C; Sklenicka J; Sayegh P; Yaffe K
    Am J Geriatr Pharmacother; 2008 Aug; 6(3):147-52. PubMed ID: 18775389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonmemory higher cognitive function and electroconvulsive treatment.
    Berenbaum SA; Taylor MA
    Psychopharmacol Bull; 1982 Apr; 18(2):101-9. PubMed ID: 7111599
    [No Abstract]   [Full Text] [Related]  

  • 59. Nitrous oxide (laughing gas) inhalation as an alternative to electroconvulsive therapy.
    Milne B
    Med Hypotheses; 2010 May; 74(5):780-1. PubMed ID: 20006916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A double blind trial of piracetam (UCB 6215) and placebo in cases of post-ECT cognitive deficiency.
    Bagadia VN; Gada MT; Mundra VK; Simon S; Doshi JM; Pradhan PV; Shah LP; Sheth UK
    J Postgrad Med; 1980 Apr; 26(2):116-20. PubMed ID: 7012328
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.